Stacy Remiszewski
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$14.7MFederal grants as PI17 awards
3Patents grantedLatest Nov 4, 2025
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
17 awards · $14.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 10, 2026 | NIH | SBIR Phase II Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | $962K | EVRYS BIO LLC |
| Jun 30, 2025 | NIH | SBIR Phase II Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | $962K | EVRYS BIO LLC |
| Apr 24, 2025 | NIH | SBIR Phase II A single antiviral to treat multiple opportunistic infections | $979K | EVRYS BIO LLC |
| Jul 18, 2024 | NIH | SBIR Phase II Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | $962K | EVRYS BIO LLC |
| Apr 8, 2024 | NIH | SBIR Phase II A single antiviral to treat multiple opportunistic infections | $984K | EVRYS BIO LLC |
| Apr 10, 2023 | NIH | SBIR Phase II A single antiviral to treat multiple opportunistic infections | $1000K | EVRYS BIO LLC |
| Aug 20, 2021 | NIH | SBIR Phase II Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | $300K | EVRYS BIO LLC |
| Aug 13, 2021 | NIH | SBIR Phase II A single antiviral to treat multiple opportunistic infections | $1.0M | EVRYS BIO LLC |
| Jul 22, 2020 | NIH | SBIR Phase II A single antiviral to treat multiple opportunistic infections | $901K | EVRYS BIO LLC |
| Jul 16, 2020 | NIH | SBIR Phase II A single antiviral to treat multiple opportunistic infections | $1.0M | EVRYS BIO LLC |
| Jul 31, 2019 | NIH | SBIR Phase II A single antiviral to treat multiple opportunistic infections | $1000K | EVRYS BIO LLC |
| Jul 23, 2019 | NIH | SBIR Phase II SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS | $1.0M | EVRYS BIO LLC |
| Sep 25, 2018 | DoD | STTR Phase I Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus | $150K | EVRYS BIO LLC with Baruch S. Blumberg Institute |
| Aug 15, 2018 | NIH | SBIR Phase II SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS | $2.0M | EVRYS BIO LLC |
| Aug 14, 2018 | NIH | SBIR Phase II SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS | $1.0M | EVRYS BIO LLC |
| Aug 5, 2016 | NIH | SBIR Phase II SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS | $305K | EVRYS BIO LLC |
| Feb 4, 2015 | NIH | SBIR Phase I An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(PML) | $225K | EVRYS BIO LLC |
4 patents as inventor
- US 11358961EVRYS BIO LLCJun 14, 2022
- US 11459321EVRYS BIO LLCOct 4, 2022
- US 12459935EVRYS BIO LLCNov 4, 2025
- US EVRYS BIO LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#17
Awards as PI#29
Patents#63
Companies
- EVRYS BIO LLCLinked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.